Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eureka Therapeutics Inc.
With
Peking University
ET190L ARTEMIS™ is a novel chimeric T-cell therapy platform that in preclinical studies, functionally matches the efficacy of CAR T cells, but dramatically reduces the release of cytokines upon killing of target-positive tumors.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with relapsed/refractory CD19+ B-cell lymphoma, with no effective therapy available per NCCN guidelines
No HCV, HIV infection, no active HBV
Liver and kidney function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) does not exceed five times the upper limit of normal range. ALT \<200U / L, bilirubin \<2.0 mg/ dL
Echocardiography or multiple gated angiogram (MUGA) ejection fraction\> 45%
ECOG performance status ≤2, expected survival time \> 3 months per PIs opinion
Women of childbearing age should have a negative pregnancy test and agree to use effective contraception during treatment and 1 year after the last dose.
Had a recurrence after at least a first-line systemic treatment
Peripheral venous access is available and no issues with apheresis for lymphocyte isolation
Voluntarily signed informed consent form
You may not be if
Women in pregnancy and lactation
Unable to perform leukapheresis and iv infusion
With active infection
Major organ failure
Continuously used glucocorticoids or other immunosuppressive agents within 4 weeks
T cell deficiency or T cells are difficult to be transduced
Clareo Health | Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
